GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GlaxoSmithKline (GSK) is conducting a Phase 1 study titled A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma. The study aims to evaluate the safety and efficacy of belantamab mafodotin combined with standard treatments in newly diagnosed multiple myeloma patients, determining the recommended phase 3 dose.
The intervention being tested is belantamab mafodotin, an experimental drug administered intravenously. It is combined with standard care drugs: bortezomib, lenalidomide, and dexamethasone, to enhance treatment effectiveness in multiple myeloma.
This interventional study is randomized and follows a sequential intervention model without masking. Its primary purpose is treatment, focusing on determining optimal dosing schedules across eight cohorts.
The study began on December 18, 2019, with its primary completion and estimated overall completion scheduled for June 24, 2025. The last update was submitted on June 24, 2025, indicating ongoing progress.
The update on this study could influence GSK’s stock performance positively by demonstrating progress in developing a promising cancer treatment. Investor sentiment may be bolstered by the potential of belantamab mafodotin to address unmet needs in multiple myeloma treatment, although competition in the oncology sector remains strong.
The study is ongoing, with further details available on the ClinicalTrials portal.